Imagine creating a master blueprint for a super-soldier immune cell that can be mass-produced in a lab. Instead of using a patient's own cells, which is slow and expensive, these cells are grown from stem cells and programmed to hunt down specific tumors. They are essentially 'pre-programmed' killers that can be stored and given to any patient immediately.
Current CAR-T therapies are often too slow or expensive because they require patient-specific cells. There is an urgent need for 'off-the-shelf' treatments for lethal cancers like glioblastoma and pancreatic cancer.
A GMP-compatible system to differentiate iPSCs into hyper-active, genetically modified NK cells capable of targeting specific tumors.
If you are a cell therapy developer dealing with the high cost of patient-specific CAR-T treatments — this project developed a GMP-compatible iPSC differentiation system that allows for the production of billions of off-the-shelf NK cells.
If you are a treatment center dealing with lethal cases of pancreatic cancer or glioblastoma — this project developed hyper-activated NK cells that remodel the tumor environment to destroy resistant malignancies.
If you are a manufacturing facility dealing with low yield in NK cell production — this project developed a novel differentiation system based on metabolic regulators to scale production to billions of cells.
Based on available project data, specific cost or pricing information is not provided.
Yes, the project uses an iPSC differentiation system designed to be easily scaled to generate billions of functional designer NK cells.
Based on available project data, specific licensing terms are not mentioned, but the project involves a consortium of 6 partners including 3 industry entities.
The iPSC culture, NK activation, and gene editing systems have been designed for GMP compliance to facilitate rapid translation to clinical trials.
The project runs from 2023-04-01 to 2026-03-31, with the goal of having a lead therapy ready for clinical trials by the end of the period.
The consortium is well-balanced for commercialization, consisting of 6 partners across 3 countries (SE, DE, DK). With a 50% industry ratio (3 companies, including 2 SMEs), the project bridges the gap between academic research and market entry, led by Magle Biopharma AB.
Contact Magle Biopharma AB in Sweden for licensing and partnership inquiries.
Contact us to explore partnership opportunities with the HyperTargIPS-NK consortium.
